Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Alfasigma S.p.A.
With
Gilead Sciences
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Males or females who may benefit from filgotinib as judged by the investigator AND who completed a Gilead sponsored filgotinib parent study for RA as outlined below:
* Have completed GS-US-417-0301, GS-US-417-0302 or GS-US-417-0303 on study drug
* OR
* Have completed GS-US-417-0302 on standard of care therapy due to RA non-responder status
Females of childbearing potential must have a negative pregnancy test prior to first dose of study drug in the long term extension (LTE)
Females of childbearing potential who engage in heterosexual intercourse must agree to protocol-approved methods of contraception
You may not be if
Diagnosis of an autoimmune or inflammatory joint disease other than RA, which would put the participant at risk by participating in the study or would interfere with study assessments/data interpretation, per judgment of the investigator
Known hypersensitivity to the study drug or its excipients
Any medical condition which would put the participant at risk by participating in the study or would interfere with study assessments/data interpretation, per judgment of the investigator
Clareo Health | Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With Rheumatoid Arthritis
